Revenues will not start yet. There is a lag time between LymPro sales and when the blood tests are actually done in the clinical trials. I would say "sales" rather than "revenues" is the critical thing to watch in January. If not "sales," then some kind of commitment or evidence Gerald can give us that Pharma is starting to embrace LymPro.
(0)
(0)
Amarantus Bioscience Holdings (AMBS) Stock Research Links